# Phase I EGFR BATs in Newly Diagnosed Glioblastoma

> **NCT03344250** · PHASE1 · COMPLETED · sponsor: **University of Virginia** · enrollment: 16 (actual)

## Conditions studied

- Glioblastoma
- Glioblastoma Multiforme

## Interventions

- **DRUG:** EGFR BATs with TMZ following SOC RT/TMZ
- **DRUG:** Weekly EGFR BATs following SOC RT/TMZ

## Key facts

- **NCT ID:** NCT03344250
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2021-12-08
- **Final completion:** 2023-05-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344250, "Phase I EGFR BATs in Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03344250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*